Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Adjuvant System AS01 is a liposome-based vaccine adjuvant containing 3-O-desacyl-4′-monophosphoryl lipid A and the saponin QS-21. AS01 has been selected for the clinical development of several candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III). Given the known immunostimulatory properties of MPL and QS-21, the objective of this study was to describe the early immune response parameters after immunization with an AS01-adjuvanted vaccine and to identify relationships with the vaccine-specific adaptive immune response. Cytokine production and innate immune cell recruitment occurred rapidly and transiently at the muscle injection site and draining lymph node postinjection, consistent with the rapid drainage of the vaccine components to the draining lymph node. The induction of Ag-specific Ab and T cell responses was dependent on the Ag being injected at the same time or within 24 h after AS01, suggesting that the early events occurring postinjection were required for these elevated adaptive responses. In the draining lymph node, after 24 h, the numbers of activated and Ag-loaded monocytes and MHCIIhigh dendritic cells were higher after the injection of the AS01-adjuvanted vaccine than after Ag alone. However, only MHCIIhigh dendritic cells appeared efficient at and necessary for direct Ag presentation to T cells. These data suggest that the ability of AS01 to improve adaptive immune responses, as has been demonstrated in clinical trials, is linked to a transient stimulation of the innate immune system leading to the generation of high number of efficient Ag-presenting dendritic cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, these results have been obtained in young mice, and it is still not known if this mechanisms are preserved in aged animals [174].”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [174]
Citations
Cites
Neutrophils in the activation and regulation of innate and adaptive immunity
Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri3024 · Cited by 3,027
Arnold, L., Henry, A., Poron, F., Baba-Amer, Y., van Rooijen, N., Plonquet, A., Gherardi, R. K., & Chazaud, B. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070075 · Cited by 2,002
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Jung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Blood Monocytes: Development, Heterogeneity, and Relationship with Dendritic Cells
Auffray, C., Sieweke, M. H., & Geissmann, F. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132557 · Cited by 1,655
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Self-citationFirst Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Self-citationA Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752 · cited 2×
“Recently, the RTS,S vaccine was shown to confer protection of 30–47% against uncomplicated and severe malaria in young African children and infants, respectively (17, 18).”
BackgroundHEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes
Girard, J.-P., Moussion, C., & Förster, R. (2012) · Nature Reviews Immunology · doi:10.1038/nri3298 · Cited by 713
Cited by
Items 201–267 of 267
Bye, W. A., Sparrow, M., Connor, S. J., Andrews, J. M., Ellard, K., Ng, W., Hume, G. E., Antoniades, S. A., & Walsh, A. J. (2017) · Internal Medicine Journal · doi:10.1111/imj.13488 · Cited by 4
Shaw, H. A., Remmington, A., McKenzie, G., Winkel, C., & Mawas, F. (2023) · Vaccines · doi:10.3390/vaccines11111724 · Cited by 4
“The following are available online at https://www.mdpi.com/article/10.3 390/vaccines11111724/s1, Figure S1: Mucosal IgA response to vaccine antigens between D21 and D36; Figure S2: SpyCEP and Mac neutralisation activity correlates with antibody geometric mean titer.”
BackgroundInfluentialADME Processes in Vaccines and PK/PD Approaches for Vaccination Optimization
Gómez‐Mantilla, J. D., Trocóniz, I. F., & Garrido, M. J. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse558 · Cited by 7
Didierlaurent, A. M., Dessart, C., & Cunningham, A. L. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216639 · Cited by 4
Self-citationHow do adjuvants enhance immune responses?
Rapaka, R. R. (2024) · eLife · doi:10.7554/elife.101259 · Cited by 4
Liu, G., Zhang, X., Wang, Y., Wang, Y., He, P. F., & Yu, Q. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2590257 · Cited by 3
“In a study by Didierlaurent et al. 32 on the vaccine adjuvant AS01, cytokine levels in the muscle tissue of mice receiving intramuscular injections of gE/ AS01 peaked within 1 day and gradually returned to baseline by day 7.”
Destexhe, É., Grosdidier, E., Bouhraoua, A., Thirion‐Delalande, C., Bouzya, B., Rouxel, R. N., Mallett, C. P., & Baumeister, J. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104625 · Cited by 3
Syntin, P., Piras-Douce, F., Dalençon, F., Garinot, M., & Haensler, J. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116358 · Cited by 4
What is Different about Recombinant Herpes Zoster Vaccine?
Park, S. Y. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.4.180 · Cited by 3
Luo, Y., Zhou, S., Song, Y., Huang, W., Wilding, G. E., Jablonski, J., Quinn, B., & Lovell, J. F. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.01.028 · Cited by 6
“Simultaneously co-localized delivery of antigen and adjuvant is necessary to elicit an optimal immune response, which was also demonstrated in AS01 (QS-21 + TLR4 agonist MPLA) and AS04 (aluminum salt + TLR4 agonist MPLA) vaccines approved by FDA [25,44].”
Levin, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00065-1 · Cited by 8
Natural Products as Possible Vaccine Adjuvants for Infectious Diseases and Cancer
Reid, A.-M., & Lall, N. (2019) · Springer eBooks · doi:10.1007/978-3-030-31269-5_9 · Cited by 3
Woziri, A. O., Meseko, C. A., Nasir, F. I., Abdulkarim, K., Fasina, F. O., Adamu, J., & Abdu, P. A. (2021) · Microbes and Infectious Diseases /Microbes and Infectious Diseases · doi:10.21608/mid.2021.72759.1149 · Cited by 3
“For instance, the subcutaneous fat beds contain few immune cells; however, they are adjacent to the skin dermal layers, which contain higher numbers of lymphocytes, macrophages, and specialized dermal dendritic cells (DCs) that drain into the local lymph node, whereas muscle tissue contains few immune cells and very l…”
BackgroundResultSallansonnet, E., Gualtieri, R., Margot, H., Mejbri, M., Posfay-Barbe, K. M., & Rohner, G. B. (2025) · Pediatric Rheumatology · doi:10.1186/s12969-025-01174-4 · Cited by 2
“Because inflammation profoundly influences vaccine-induced immune responses, vaccination offers a unique opportunity to assess adaptive immune function in children with PFAPA [30–33].”
Combination adjuvants: clinical value and mechanisms of action
Madelon, N., & Didierlaurent, A. M. (2026) · Current Opinion in Virology · doi:10.1016/j.coviro.2026.101564 · Cited by 2
Self-citationRoman, F. P., Coccia, M., & Schuerman, L. (2020) · Malaria Journal · doi:10.1186/s12936-020-03334-1 · Cited by 2
Levin, M. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00066-9 · Cited by 2
Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant
Larsen, S. E., Rais, M., Reese, V. A., Ferede, D., Pecor, T., Kaur, S., Nag, D., Smytheman, T., Gray, S. A., Carter, D., et al. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlaf014 · Cited by 2
“There are several candidates in the clinical TB pipeline for-matted as subunit protein-adjuvants including: (i) M72 fusion protein þ AS01, a liposomal formulation of MPL (TLR4 agonist) and the saponin QS-21, 71–74 (ii) ID93 fusion protein þ GLA-SE (TLR4 agonist), 36,75,76 (iii) H56 antigen þ anti-bacterial peptide (KL…”
Mandefro, A., Messele, A., Katsvanga, M., Cham, F., Oriero, E. C., Amambua‐Ngwa, A., & Golassa, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-00140-0 · Cited by 2
“Furthermore, it has been well-documented that vaccine efficacy decreases against non-matched vaccine haplotypes, indicating that allele-specific immunity plays a critical role in providing protection 17,18 .”
Cunningham, A. L., Levin, M. J., & Heineman, T. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00004-5 · Cited by 2
Immunosenescence Modulation by Vaccination
McElhaney, J. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_71 · Cited by 2
“The enhanced adaptive immune response to the glycoprotein E is dependent on AS01-mediated activation of dendritic cells and increased antigen presentation to the CD4+ T cells (Didierlaurent et al. 2014).”
BackgroundTechnologies for Making New Vaccines
Pecetta, S., Ahmed, S., Ellis, R. W., & Rappuoli, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00067-0 · Cited by 2
Yu, R., Guo, Y., Zhang, S., Ai, Y., Wei, R., Li, Y., Chen, H., Liu, S., Zhang, C., Yao, Y., et al. (2025) · Vaccines · doi:10.3390/vaccines13111162 · Cited by 2
Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice
Quan, Y., Luo, S., Wu, S., Wang, K., Hu, L., Yihuan, H. A. O., Xu, K., & Liu, Y. (2025) · Viruses · doi:10.3390/v18010053 · Cited by 1
“Consistent with previous reports [62], neutrophils are the first to respond, followed by a rapid increase in monocytes within 24 h, which are one of the most abundantly recruited innate immune cell populations.”
Rincón-Arévalo, H., Halleck, F., Bőgér, D., Rosenlehner, E., Stefanski, A., Carli, C., Avaniadi, P. D., Bachmann, F., Dreveton, L. S., Henning, A., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag002 · Cited by 2
Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development
Turan, G., Boggio, M. J., Othman, A. S., Nnaemeka, V., Hill, A. V. S., & Salman, A. M. (2026) · Vaccines · doi:10.3390/vaccines14030277 · Cited by 2
“AS01, a liposome-based adjuvant system containing 3-O-desacyl-4 ′ - MPLA and QS-21, is used in the RTS,S vaccine and elicits both strong T cell-mediated and humoral immune responses [9,125].”
SQUALENE IMMUNOGENICITY DETERMINATION AS AN ADJUVANT
Soliman, M., Eid, F., & Aly., A. (2016) · International Journal of Advanced Research · doi:10.21474/ijar01/1761 · Cited by 1
Preventing Infections and Healthy Aging
McElhaney, J. E., Andrew, M. K., McNeil, S., & Kuchel, G. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-06200-2_16 · Cited by 1
Immunosenescence Modulation by Vaccination
McElhaney, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_71-1 · Cited by 1
Okumoto, A., Nomura, Y., Maki, K., Ogawa, T., Onodera, H., Shikano, M., & Okabe, N. (2023) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2023.105413 · Cited by 1
Zhang, Y., Zhou, Y., Gong, M., Zhang, Q., Zheng, Q., Shen, Y., Lu, W., & Jiang, S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300253 · Cited by 6
Head-to-Head Comparison of Novel Vaccine Technologies Comes with a Minefield of Challenges
Christensen, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010012 · Cited by 1
“This, combined with stimulation through the TLR4 receptor, induces the production of proinflammatory cytokines and chemokines that prime the APCs to mediate a Th1-type immune response [31,32].”
BackgroundVekemans, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-45210-4_7 · Cited by 1
Herpes zoster: The changing landscape
Caldera, F., Ninos, C., & Hayney, M. S. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2017.01.007 · Cited by 1
Loiseau, C., Traoré, B., Ongoïba, A., Kayentao, K., Doumbo, S., Doumtabé, D., de Sousa, K. P., Brady, J. L., Proietti, C., Crompton, P. D., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1265 · Cited by 2
“RTS,S/AS01, also known as Mosquirix, is the most advanced malaria vaccine candidate.(3,4) However, multiple studies have demonstrated that its efficacy is suboptimal, too low to achieve malaria eradication, and wanes over time, especially in highly exposed populations.”
BackgroundMcNair, D., Hu, H., & Selwyn, C. (2021) · Gates Open Research · doi:10.12688/gatesopenres.13329.1
“Another hypothesized protection mechanism involves induction of augmented adaptive immune responses through dendritic cell activation and innate immune cell recruitment with certain contemporary adjuvants such as Adjuvant System AS01, which is a liposome-based vaccine adjuvant containing 3-O-desacyl4’-monophosphoryl l…”
BackgroundBorriello, F., Spreafico, R., Poli, V., Chou, J. S., Barrett, N. A., Lacanfora, L., Franco, M. E., Marongiu, L., Iwakura, Y., Pucci, F., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.03.973727 · Cited by 1
“The dLN has been thoroughly scrutinized for its capacity to host adaptive immune responses, but recent reports highlight that activation of immune cells in the peripheral tissue and migration of these cells to the dLN also elicit an antigen-independent lymph node innate response (LIR) (5-13).”
BackgroundBerzofsky, J. A., Howe, S. B., & Olkhanud, P. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00211-1 · Cited by 4
Development of Dry Powder Formulations of AS01 B containing vaccines using Thin-Film Freeze-DryingPreprint
AboulFotouh, K., Xu, H., Williams, R. O., & Cui, Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.27.482135 · Cited by 1
Fergusson, J. R., Siu, J. H. Y., Gupta, N., Nee, E., Reinke, S., Ströbel, T., Bhalla, A., Kandage, S. M., Courant, T., Hill, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.21.608943 · Cited by 1
Adjuvanted Herpes Zoster Subunit Vaccine
Aerssens, A., & Leroux-Roels, G. G. (2015) · Future Virology · doi:10.2217/fvl.15.105
O’Hagan, D. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.15001-7
Exported proteins and their role in Plasmodium infection
Loh, H. P. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/100418
Dieng, C. C., Ford, C. T., Lerch, A., Donu, D., Huynh, J., Vegesna, K., Guo, J., Janies, D. A., Amoah, L. E., Afrane, Y. A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000573
Vaccines against viral infections
McElhaney, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198701590.003.0088
Tijtgat, J., Schwarze, J. K., Mijnsbrugge, A.-S. V., Raeymaeckers, S., Riet, I. V., Geeraerts, X., Stevens, L., Tuyaerts, S., & Neyns, B. (2022) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2022-sitc2022.0790
Vaccine Adjuvants: Mechanisms of Action
HogenEsch, H., Orr, M. T., & Fox, C. B. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162572-00214 · Cited by 2
Sheng, J., Tao, K., Zhang, C., Zhang, A., Yang, L., & Ji, J. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1607236
A Review of WHO-recommended 21/Matrix-MTM vaccine for the prevention of malaria
Lauya, L., & Dahal, A. (2024) · The Evidence · doi:10.61505/evidence.2024.2.4.90
Kuipers, S. D., Knoester, M., Hazenberg, C. L. E., van Baarle, D., & van der Heiden, M. (2025) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2025.100231
Liu, X., Gong, S., Xu, J., Wei, Y., Chen, X., Wu, Y., Zhang, Z., Ma, J., Yang, Y., & Tan, S. (2025) · Vaccines · doi:10.3390/vaccines13111124
“The AS01 adjuvant consists of QS21 and monophosphoryl lipid A (MPL) [8].”
Nanostructured lipid-based adjuvants and delivery systems for antiviral vaccine development
Zhao, Y., Cheng, Z., Cai, D., Fang, Y.-L., Xu, J., Dai, H., Liu, W., & Zhang, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112059
Plasmodium vivax circumsporozoite protein and vaccine strategies in murine models: A scoping review
Sampaio, M. P., Cerilo-Filho, M., de Almeida, M. F. C., Matos, M. A. T., Silva, A. A., Fernando, D. J. V., Bras, R. P., Rossit, A. R. B., de Castro, T. X., & Machado, R. L. D. (2025) · Experimental Parasitology · doi:10.1016/j.exppara.2025.109081
Galgani, I., Annaratone, M., Casula, D., Maro, G. D., Janssens, M., Tasciotti, A., Schwarz, T., Ferguson, M., & Arora, A. K. (2022) · Figshare · doi:10.6084/m9.figshare.19711081
Tijtgat, J. (2022) · VUBIR (Vrije Universiteit Brussel)
Maxwell, J., Joyner, J. A., Norton, J. E., Knapp, W., Wang, I., Swaminathan, G., Monslow, M. A., & Citron, M. P. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2689208
“120,121 While the efficacy of this adjuvant is supported by real-world evidence, 122 its mechanism of action, as well as the ability of adjuvants with comparable immunostimulatory properties to produce similar effects, remains to be documented.”
Grobben, M., Kerster, G., Rijnstra, E. S.-V., Brinkkemper, M., Poniman, M., Burger, J. A., Tejjani, K., van Rijswijk, J., Iddouch, W. A., Oomen, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.23.733553
Jackson, L., Williams, S., Sinclair, J., Kume, A., Bahadoran, A., Langohr, I. M., Danz, H., Lu, B., Bangari, D. S., Cox, A. J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1831403
King, H. A. D., Subra, C., Tourtellott‐Fogt, E., Swafford, I., Basu, S., Rossman, M. J., Phillips, L., Obarorakpor, N., Ding, S., Ferrari, M. G., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00389-26
“Mechanisms underlying CD8 + T cell responses to adjuvanted protein are not well understood, but antigen cross-presentation has been observed for other saponin-and MPL-based adjuvants, such as AS01 and ISCOMATRIX (75, 76).”
Wei, L., Zhu, W., Dong, C., Kim, J. K., Arsana, A., Omotara, P., Ferrante, A., Morris, W. R., Kim, H., Denning, T. L., et al. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103008
Pereira, P. S., Neri, J. C. S., Oliveira-de-Souza, D., Andrade, B. B., & Barreto‐Duarte, B. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag578 · Cited by 1
“This pattern of symptoms aligns with the expected transient inflammatory response to AS01-adjuvanted vaccination, with markers returning to baseline by ∼ 7 days and events re-solving without intervention [23–26].”
Poe, M., Neokosmidis, N., Hernandez-Franco, J. F., Stiving, A. Q., Payne, E. M., Kummar, S., Xiong, J., Wagner, A., Foley, D. A., DiStefano, D. J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1916491
“Following intramuscular injection of AS01, adjuvant rapidly reaches the draining lymph node and induces chemokine and cytokines both at the injection site and the lymph node (20, 21).”
InfluentialPreclinical Evaluation of the SMNP-Adjuvanted R21 Malaria Vaccine Across Multiple Mouse Strains
Turan, G., Fedorova, K., Hill, A. V. S., & Salman, A. M. (2026) · Vaccines · doi:10.3390/vaccines14100861
“More complex systems, such as AS01, combine innate immune receptor stimulation with particulate delivery, thereby enhancing both humoral and T-cell-mediated immunity [8,9].”
Tang, J., Balaji, S., & Oon, H. H. B. (2026) · Vaccines · doi:10.3390/vaccines14100879
“MPL works together with QS-21 to enhance the immune response to the co-administered antigen by producing IFN-γ , given that IFN-γ generally inhibits viral replication, also enhancing T cell responses and antibody isotype switching [36,94,95].”
Saha, A., Mosteiro, A., Plata, A., Pifferi, C., Baschirotto, P. T., Oyenarte, I., Ereño‐Orbea, J., Azkargorta, M., Elortza, F., Anguíta, J., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.5055772
Saha, A., Mosteiro, A., Plata, A., Pifferi, C., Baschirotto, P. T., Oyenarte, I., Ereño‐Orbea, J., Azkargorta, M., Elortza, F., Anguíta, J., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.5055772
Human in vitro modeling of adjuvants
Haren, S. V. (2025) · ImmPort · doi:10.21430/m3x8ftktpf
Metadata
- Authors
- Didierlaurent, A. M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B. N., Garçon, N., Van Mechelen, M., & Morel, S.
- Affiliations
- GlaxoSmithKline (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Centre National de la Recherche Scientifique (FR)
- GlaxoSmithKline Vaccines , 1330 Rixensart ,
- Corresponding author
- Collignon, Catherine
- Bourguignon, Patricia
- Wouters, Sandrine
- Fochesato, Michel
- Dendouga, Najoua
- Langlet, Christelle
- Morel, Sandra
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-08
- Volume
- 193
- Issue
- 4
- Pages
- 1920-1930
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1942950379
- Cited by
- 266
- References
- 56
- Citations by year
- 2026: 14 · 2025: 25 · 2024: 15 · 2023: 23 · 2022: 31 · 2021: 26 · 2020: 19 · 2019: 28 · 2018: 14 · 2017: 37 · 2016: 21 · 2015: 10 · 2014: 2
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- MPL, QS-21, dendritic cells, adaptive immune response, antigen presentation, MHC class II, monocytes, draining lymph nodes, cytokine production, innate immune activation, RTS,S malaria vaccine, varicella-zoster vaccine, T cell response, antibody response
- MeSH terms
- Adjuvants, Immunologic, Animals, Histocompatibility Antigens Class II, B-Lymphocytes, Dendritic Cells, Drug Combinations, Female, Humans, Lipid A, Lymphocyte Activation, Mice, Inbred C57BL, Monocytes, Saponins, Vaccination, Vaccines, CD4-Positive T-Lymphocytes, Antigen Presentation, CD8-Positive T-Lymphocytes, Mice, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.